April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • M. N. Lott
    Satilla Ophthalmology Associates, Waycross, Georgia
  • H. Singh
    Southeast Retina Center, Augusta, Georgia
  • J. Singh
    Southeast Retina Center, Augusta, Georgia
  • D. M. Marcus
    Southeast Retina Center, Augusta, Georgia
    Ophthalmology, University of South Carolina School of Medicine, Columbia, South Carolina
  • Footnotes
    Commercial Relationships  M.N. Lott, None; H. Singh, Genentech, F; Regeneron, F; Eyetech, F; Schering-Plough, F; OPKO, F; Eli-Lilly, F; Allergan, F; Alcon, F; Alimaera, F; DORC, F; OphthoTech, F; Neovista, F; Pfizer, F; Thrombogenics, F; J. Singh, None; D.M. Marcus, Regeneron, F; Alcon, F; OPKO, F; Alimaera, F; Schering-Plough, F; DORC, F; Eyetech, F; Thrombogenics, F; Allergan, F; Genentech, F; OphthoTech, F; Neovista, F; Pfizer, F; Eli-Lilly, F; Genentech, C; Eyetech, C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 6200. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. N. Lott, H. Singh, J. Singh, D. M. Marcus; Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):6200.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To investigate the safety and efficacy of intravitreal ranibizumab in the treatment of polypoidal choroidal vasculopathy (PCV).

Methods: : Phase I/II safety study; prospective, open-label, single-center, non-randomized, uncontrolled, consecutive interventional case series. Enrolled patients were >35 years old and displayed exudative, active PCV in 1 eye. PCV was defined as choroidal neovascularization that displayed occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography. Eyes received 3 consecutive, monthly intravitreal ranibizumab injections (0.5 mg or 0.3 mg/0.05 cc) followed by monthly evaluations with the option of additional intravitreal ranibizumab or alternative treatments at the discretion of the investigator. Baseline and follow-up evaluations included medical history, blood pressure, physical examination, best-corrected ETDRS visual acuity (BCVA), intraocular pressure measurement, complete ophthalmologic examination, fundus photography, fluorescein/ICG angiography, and optical coherence tomography (OCT).

Results: : Twenty eyes of 20 subjects were enrolled. Subjects included 17 African-Americans (12 female, 5 male) and 3 male Caucasians. The mean age was 63.6 years (range, 37-86) and the mean follow-up was 13 months (range, 1-24 months). Mean baseline BCVA and OCT central subfield thickness were 20/127 (range, 20/20-20/500) and 302 microns (range, 122-607), respectively. After the first three ranibizumab injections, mean BCVA was 20/116 (range, 20/20-20/400) and mean OCT thickness was 233 microns (range, 130-378). At last follow-up visit, mean BCVA was 20/79 (range, 20/20-20/400) and mean OCT thickness decreased to 233 microns (range, 135-449). At the last follow-up visit, 13, 7, and 0 eyes demonstrated improved, unchanged, and worsened BCVA, respectively. Complications included macular hole development in 1 eye that had vitreous and subretinal hemorrhage present at enrollment; posterior vitreous detachment with mild vitreous hemorrhage in 1 eye; and cataract progression, requiring cataract extraction, in 2 patients.

Conclusions: : In a small prospective study, intravitreal ranibizumab was safe and resulted in decreased retinal thickness and improved visual acuity in the majority of eyes with PCV.

Clinical Trial: : www.clinicaltrials.gov NCT00837330

Keywords: choroid: neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.